The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Change in metabolic tumor activity on 18F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.
 
Erik Jacobus Van Helden
No Relationships to Disclose
 
Catharina Wilhelmina Menke
Research Funding - GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Eline Boon
No Relationships to Disclose
 
Suzanne van Es
No Relationships to Disclose
 
Marc C. Huisman
No Relationships to Disclose
 
Derk Jan De Groot
No Relationships to Disclose
 
Ronald Boellaard
No Relationships to Disclose
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - MSD (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Synthon (Inst)
 
Elisabeth De Vries
Consulting or Advisory Role - Medivation (Inst); Merck (Inst); Synthon (Inst)
Research Funding - Amgen (Inst); Chugai Pharma (Inst); CytomX Therapeutics (Inst); Nordic Nanovector (Inst); Novartis (Inst); Radius Health (Inst); Roche/Genentech (Inst); SERVIER (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - Merck
 
Otto S. Hoekstra
No Relationships to Disclose
 
Henk M.W. Verheul
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Merck (Inst)
Research Funding - Amgen (Inst); Immunovo (Inst); Novartis (Inst); Roche (Inst); Vitromics (Inst)